Genomic Health (GHDX) Lowered to “Sell” at ValuEngine

ValuEngine downgraded shares of Genomic Health (NASDAQ:GHDX) from a hold rating to a sell rating in a research report sent to investors on Thursday.

A number of other brokerages have also issued reports on GHDX. Zacks Investment Research lowered shares of Genomic Health from a hold rating to a strong sell rating in a research report on Friday, March 9th. William Blair lowered shares of Genomic Health from an outperform rating to a market perform rating in a report on Wednesday, December 20th. Barclays reiterated a sell rating and issued a $28.00 price target on shares of Genomic Health in a report on Monday, January 8th. Piper Jaffray reiterated a hold rating and issued a $33.00 price target on shares of Genomic Health in a report on Thursday, March 8th. Finally, BidaskClub upgraded shares of Genomic Health from a hold rating to a buy rating in a report on Friday, March 30th. Four equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and one has assigned a buy rating to the company. Genomic Health presently has an average rating of Hold and an average target price of $32.67.

How to Become a New Pot Stock Millionaire

Shares of NASDAQ GHDX opened at $32.23 on Thursday. Genomic Health has a 1 year low of $26.54 and a 1 year high of $37.50. The company has a market cap of $1,138.49, a P/E ratio of 3,223.00 and a beta of 0.63.

Genomic Health (NASDAQ:GHDX) last announced its earnings results on Thursday, March 8th. The medical research company reported $0.08 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.09 by ($0.01). Genomic Health had a negative return on equity of 0.83% and a negative net margin of 1.13%. The firm had revenue of $87.50 million for the quarter, compared to analyst estimates of $88.96 million. During the same quarter last year, the business posted $0.04 EPS. The firm’s revenue was up 5.8% compared to the same quarter last year. analysts forecast that Genomic Health will post 0.42 EPS for the current year.

In other news, COO G Bradley Cole sold 5,000 shares of the firm’s stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $32.89, for a total value of $164,450.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Kimberly J. Popovits sold 10,000 shares of the firm’s stock in a transaction on Wednesday, February 14th. The shares were sold at an average price of $32.93, for a total transaction of $329,300.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 39,942 shares of company stock worth $1,317,895. 46.20% of the stock is owned by company insiders.

Hedge funds have recently modified their holdings of the company. Wells Fargo & Company MN raised its stake in shares of Genomic Health by 12.8% in the 3rd quarter. Wells Fargo & Company MN now owns 68,884 shares of the medical research company’s stock valued at $2,211,000 after acquiring an additional 7,809 shares during the period. Emory University raised its stake in shares of Genomic Health by 17.8% in the 4th quarter. Emory University now owns 62,926 shares of the medical research company’s stock valued at $2,152,000 after acquiring an additional 9,487 shares during the period. Russell Investments Group Ltd. raised its stake in shares of Genomic Health by 38.5% in the 3rd quarter. Russell Investments Group Ltd. now owns 22,670 shares of the medical research company’s stock valued at $727,000 after acquiring an additional 6,304 shares during the period. OxFORD Asset Management LLP purchased a new position in shares of Genomic Health in the 3rd quarter valued at $307,000. Finally, Dupont Capital Management Corp purchased a new position in shares of Genomic Health in the 4th quarter valued at $1,103,000. 89.99% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Genomic Health (GHDX) Lowered to “Sell” at ValuEngine” was originally reported by Week Herald and is owned by of Week Herald. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at https://weekherald.com/2018/04/23/genomic-health-ghdx-lowered-to-sell-at-valuengine.html.

Genomic Health Company Profile

Genomic Health, Inc, a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply